Interaction Checker

Interaksi Omalizumab

Omalizumab (Xolair) memiliki 24 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 24 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (24)

  • Azelastin dan flutikasonantihistaminModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • Tembakau dan merokokTembakau dan ganjaModerat

    The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (label Omalizumab, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

Periksa Omalizumab terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.